214 related articles for article (PubMed ID: 17051669)
1. [Assessment and truth -- how many cardio- and cerebrovascular events are in fact to be led back to taking rofecoxib].
Mühlbauer B; Timm J
Med Klin (Munich); 2006 Aug; 101(8):673-5; author reply 678-9. PubMed ID: 17051669
[No Abstract] [Full Text] [Related]
2. [How many harmed by rofecoxib in Germany?].
Scharnetzky E; Andersohn F; Schill W; Garbe E; Pigeot I
Med Klin (Munich); 2006 Aug; 101(8):675-6; author reply 678-9. PubMed ID: 17051670
[No Abstract] [Full Text] [Related]
3. [Overestimated].
Höer A; Häussler B
Med Klin (Munich); 2006 Aug; 101(8):676-7; author reply 678-9. PubMed ID: 17051671
[No Abstract] [Full Text] [Related]
4. Balancing the cyclooxygenase portfolio.
Armstrong PW
CMAJ; 2006 May; 174(11):1581-2. PubMed ID: 16717266
[No Abstract] [Full Text] [Related]
5. Observational studies and the withdrawal of rofecoxib.
Watson DJ; Santanello NC
Pharmacoepidemiol Drug Saf; 2006 Mar; 15(3):199-201; author reply 203-5. PubMed ID: 16508998
[No Abstract] [Full Text] [Related]
6. Adverse cardiovascular effects of rofecoxib.
Furberg CD
N Engl J Med; 2006 Jul; 355(2):204; author reply 204-5. PubMed ID: 16838442
[No Abstract] [Full Text] [Related]
7. Persistence of cardiovascular risk after rofecoxib discontinuation.
Ross JS; Madigan D; Konstam MA; Egilman DS; Krumholz HM
Arch Intern Med; 2010 Dec; 170(22):2035-6. PubMed ID: 21149763
[No Abstract] [Full Text] [Related]
8. Adverse cardiovascular effects of rofecoxib.
Nissen SE
N Engl J Med; 2006 Jul; 355(2):203-4; author reply 203-5. PubMed ID: 16801355
[No Abstract] [Full Text] [Related]
9. Peptic ulcer and bleeding events associated with rofecoxib in a 3-year colorectal adenoma chemoprevention trial.
Lanas A; Baron JA; Sandler RS; Horgan K; Bolognese J; Oxenius B; Quan H; Watson D; Cook TJ; Schoen R; Burke C; Loftus S; Niv Y; Ridell R; Morton D; Bresalier R
Gastroenterology; 2007 Feb; 132(2):490-7. PubMed ID: 17258718
[TBL] [Abstract][Full Text] [Related]
10. COX-2 selective inhibitors and heart health.
Simon LS; White WB
Postgrad Med; 2005 Jan; 117(1 Suppl):7-20. PubMed ID: 19667717
[TBL] [Abstract][Full Text] [Related]
11. Cardiac risks with COX-2 inhibitors.
Ashworth AJ
CMAJ; 2007 Feb; 176(4):489-92. PubMed ID: 17296963
[No Abstract] [Full Text] [Related]
12. [Rofecoxib increases myocardial infarction risk in seniors].
Wasielewski S
Med Monatsschr Pharm; 2005 Nov; 28(11):416-7. PubMed ID: 16309032
[No Abstract] [Full Text] [Related]
13. [Slime fight in the lay media. Were the Vioxx fatal cases kept secret?].
Zierenberg O
MMW Fortschr Med; 2004 Oct; 146(43):60. PubMed ID: 15559526
[No Abstract] [Full Text] [Related]
14. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
[TBL] [Abstract][Full Text] [Related]
15. Cerebrovascular events after discontinuation of rofecoxib treatment.
Andersohn F
Cardiovasc Drugs Ther; 2007 Apr; 21(2):77-9. PubMed ID: 17404824
[No Abstract] [Full Text] [Related]
16. The withdrawal of rofecoxib.
Arellano FM
Pharmacoepidemiol Drug Saf; 2005 Mar; 14(3):213-7. PubMed ID: 15724267
[No Abstract] [Full Text] [Related]
17. [Assessment of the number of cardio- and cerebrovascular events due to rofecoxib (Vioxx) in Germany between 2001 and 2004].
Sawicki PT; Bender R; Selke GW; Klauber J; Gutschmidt S
Med Klin (Munich); 2006 Mar; 101(3):191-7. PubMed ID: 16648975
[TBL] [Abstract][Full Text] [Related]
18. [Use of rofecoxib in family practice in the north of Netherlands, 2000-2004: background and consequences].
van der Veen WJ; van der Werf GT
Ned Tijdschr Geneeskd; 2006 May; 150(18):1016-21. PubMed ID: 16715866
[TBL] [Abstract][Full Text] [Related]
19. COX-2 inhibitors and the heart: putting risk in perspective.
Bobadilla RV; Barnett EM; Randels CL
Adv Nurse Pract; 2005 Nov; 13(11):48-50. PubMed ID: 16295003
[No Abstract] [Full Text] [Related]
20. Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
Spalding WM; Reeves MJ; Whelton A
Am J Ther; 2007; 14(1):3-12. PubMed ID: 17303969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
